Skip to main content
logo
Becton, Dickinson and Company (BVMF:B1DX34)
Brazil flag Brazil · Delayed Price · Currency is BRL
211.27
-7.19 (-3.29%)
At close: Jan 2, 2026

Revenue Breakdown

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
Medication Delivery Solutions Revenue
4.58B
Log In
Log In
Log In
Upgrade
Medication Management Solutions Revenue
3.47B
Log In
Log In
Log In
Upgrade
Pharmaceutical Systems Revenue
2.32B
Log In
Log In
Log In
Upgrade
Advanced Patient Monitoring Revenue
1.08B
Log In
Log In
Log In
Upgrade
Specimen Management Revenue
1.87B
Log In
Log In
Log In
Upgrade
Diagnostic Solusions Revenue
1.84B
Log In
Log In
Log In
Upgrade
Integrated Diagnostic Solutions Revenue
3.71B
Log In
Log In
Log In
Upgrade
Biosciences Revenue
1.46B
Log In
Log In
Log In
Upgrade
Surgery Revenue
1.57B
Log In
Log In
Log In
Upgrade
Peripheral Intervention Revenue
2.00B
Log In
Log In
Log In
Upgrade
Urology and Critical Care Revenue
1.65B
Log In
Log In
Log In
Upgrade
Revenue (Other)
-3.71B
Log In
Log In
Log In
Upgrade
Revenue (Total)
21.84B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
United States Revenue
12.79B
Log In
Log In
Log In
Upgrade
International Revenue
9.05B
Log In
Log In
Log In
Upgrade
Revenue (Other)
1.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
21.84B
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
Medical Revenue
11.46B
Log In
Log In
Log In
Upgrade
Life Sciences Revenue
5.17B
Log In
Log In
Log In
Upgrade
Interventional Revenue
5.22B
Log In
Log In
Log In
Upgrade
Revenue (Total)
21.84B
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
Medical Segment Operating Income
4.14B
Log In
Log In
Log In
Upgrade
Life Sciences Segment Operating Income
1.64B
Log In
Log In
Log In
Upgrade
Interventional Segment Operating Income
2.25B
Log In
Log In
Log In
Upgrade
Operating Income (Total)
2.58B
Log In
Log In
Log In
Upgrade

EBIT 2

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
Medical Segment Operating Income (Pre-FY2025 Reporting)
-
Log In
Log In
Log In
Upgrade
Life Sciences Segment Operating Income (Pre-FY2025 Reporting)
-
Log In
Log In
Log In
Upgrade
Interventional Segment Operating Income (Pre-FY2025 Reporting)
-
Log In
Log In
Log In
Upgrade
Operating Income (Total)
2.58B
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.